中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

124 records (took 0.022 seconds)

    Faster shift value calculation using modified carry-lookahead adder
    42.
    发明授权
    Faster shift value calculation using modified carry-lookahead adder 失效
    使用改进的进位前瞻加法器更快地移位值计算

    公开(公告)号：US07444366B2

    公开(公告)日：2008-10-28

    申请号：US10853518

    申请日：2004-05-26

    Applicant: Paul R. Thayer ,  Sanjay Kumar

    Inventor： Paul R. Thayer ,  Sanjay Kumar

    IPC: G06F7/38 ,  G06F7/50

    CPC classification number: G06F7/5055 ,  G06F7/508 ,  H03K19/0963

    Abstract: Circuitry for reducing propagation delays in calculation of a value for use in a floating point multiply-accumulate operation. In the circuitry, a carry-save adder receives values of three input operands from three latches. A carry-lookahead adder receives the outputs from the carry-save adder and implements an XOR operation on a most-significant bit along with its own logic operation to produce the value for the floating point multiply-accumulate operation. Modification of the carry-lookahead adder to perform the XOR operation results in elimination of an entire stage of logic.

    Abstract translation: 用于减少在浮点乘法运算中使用的值的计算中的传播延迟的电路。 在电路中，进位保存加法器从三个锁存器接收三个输入操作数的值。 进位 - 前瞻加法器接收来自进位保存加法器的输出，并在最高有效位上执行XOR运算以及其自身的逻辑运算，以产生浮点乘法运算的值。 进位前瞻加法器的修改以执行异或运算导致消除整个逻辑级。

    PROCESS FOR THE PRODUCTION OF PORTLAND SLAG CEMENT USING GRANULATED BLAST FURNACE SLAG
    43.
    发明申请
    PROCESS FOR THE PRODUCTION OF PORTLAND SLAG CEMENT USING GRANULATED BLAST FURNACE SLAG 失效
    使用颗粒状火山灰浆生产波特兰泥浆水泥的方法

    公开(公告)号：US20080022903A1

    公开(公告)日：2008-01-31

    申请号：US11491916

    申请日：2006-07-25

    Applicant: Rakesh Kumar ,  Sanjay Kumar ,  Amitava Bandopadhaya ,  Surya Pratap Mehrotra

    Inventor： Rakesh Kumar ,  Sanjay Kumar ,  Amitava Bandopadhaya ,  Surya Pratap Mehrotra

    IPC: C04B7/19 ,  C04B7/14 ,  C04B2/10

    CPC classification number: C04B28/04 ,  C04B18/141 ,  Y02W30/94 ,  C04B20/008 ,  C04B20/026

    Abstract: Accordingly, the present invention provides an improved process for the production of Portland slag cement using granulated blast furnace slag, which comprises: (viii) forming of cement clinker by known process, (ix) ball-milling of cement clinker for a period ranging between 30-60 minutes in dry condition, (x) reducing size of granulated blast furnace slag by any process to obtain the size in the range between 210 to 100 μm for using as feed for attrition mill, (xi) wet milling of granulated blast furnace slag for a period ranging between 5-15 minutes in an attrition mill using granulated blast furnace slag to water ratio in the range of 1:1 to 1:2 and granulated blast furnace slag to grinding bail ratio in the range of 1:5 to 1:15, (xii) removing water from the slurry obtained after attrition milling by known process, (xiii) drying of the obtained slurry by known process, (xiv) mixing intimately of: attrition milled slag obtain in step (vi) in the range of: 50 to 95% by weight ball-milled clinker obtain in step (ii) in the range of: 05 to 45% by weight gypsum in the range of: 01 to 05% by weight for a period in the range of 15 to 30 minutes.

    Abstract translation: 因此，本发明提供了一种使用造粒高炉矿渣生产波特兰矿渣水泥的改进方法，其包括：（viii）通过已知方法形成水泥熟料，（ix）水泥熟料的球磨，时间范围 在干燥条件下30-60分钟，（x）通过任何工艺减少造粒高炉矿渣的尺寸，以获得用于磨粉机进料的210至100um之间的尺寸，（xi）造粒高炉的湿磨 在磨粉机中使用造粒高炉矿渣与水的比例在1：1至1：2范围内的炉渣在5-15分钟之间，并将造粒高炉矿渣与1：5至 （xii）通过已知方法磨碎后得到的浆料中的水，（xiii）通过已知方法干燥所获得的浆料，（xiv）密切混合：步骤（vi）中获得的磨碎的炉渣 范围：50〜95重量％ 研磨熟料在步骤（ii）中获得的范围为：05至45重量％的石膏，其范围为：01至05重量％，范围为15至30分钟。

    Identification and use of cofactor independent phosphoglycerate mutase as a drug target for pathogenic organisms and treatment of the same
    45.
    发明申请
    Identification and use of cofactor independent phosphoglycerate mutase as a drug target for pathogenic organisms and treatment of the same 审中-公开
    鉴定和使用辅因子独立磷酸甘油酸变位酶作为致病生物体的药物靶点及其治疗

    公开(公告)号：US20060111848A1

    公开(公告)日：2006-05-25

    申请号：US11316521

    申请日：2005-12-22

    Applicant: Clotilde Carlow ,  Yinhua Zhang ,  Jeremy Foster ,  Sanjay Kumar

    Inventor： Clotilde Carlow ,  Yinhua Zhang ,  Jeremy Foster ,  Sanjay Kumar

    IPC: G06F19/00

    CPC classification number: C12N9/90 ,  C12Q1/18 ,  G16B10/00 ,  G16B20/00 ,  G16B30/00

    Abstract: Present embodiments of the invention describe computational methods for performing a systematic, genome-wide search for novel drug targets in pathogenic organisms for example, the human filarial parasites. Cofactor independent phosphoglycerate mutase (iPGM) was identified by this search as a candidate target for identifying therapeutic agents for use in treating animal or plant subjects infected with parasitic nematodes, microbial pathogens including microsporidia, fungi etc. A consensus amino acid or nucleotide sequence that characterizes iPGM is further provided.

    Abstract translation: 本发明的现有实施方案描述了用于在致病生物体（例如人类丝虫）中进行系统的全基因组搜索新型药物靶标的计算方法。 通过该搜索将辅因子独立的磷酸甘油酸变位酶（iPGM）鉴定为用于鉴定用于治疗感染寄生线虫，包括微孢子虫，真菌等的微生物病原体的动物或植物受试者的治疗剂的候选靶标。表征的共有氨基酸或核苷酸序列 还提供iPGM。

    Metrics capability self assessment
    46.
    发明申请
    Metrics capability self assessment 有权
    指标能力自我评估

    公开(公告)号：US20050144592A1

    公开(公告)日：2005-06-30

    申请号：US10745989

    申请日：2003-12-24

    Applicant: Paul Below ,  Debra Maschino ,  Sanjay Kumar ,  Lynne Palmer ,  Dorothy Easterday

    Inventor： Paul Below ,  Debra Maschino ,  Sanjay Kumar ,  Lynne Palmer ,  Dorothy Easterday

    IPC: G06F9/44

    CPC classification number: G06Q10/06

    Abstract: A method, system, and computer program product for systematically collecting metrics implementation data for use by an enterprise is provided. In one embodiment, a metrics capability self assessment (MCSA) system determines a set of information sections important in determining implementation of metrics in an organization within the enterprise. The MCSA system also determines a set of questions for each information section which measure the degree of implementation of metrics within a given one of set of information sections. These are typically determined by a group within the enterprise and entered into the MCSA system. The MCSA system then provides a user with the set of questions and receives responses to the set of questions. These questions are presented to each organization and project site within the organization on a periodic basis to ensure a systematic collection of information. Based on the answers, a scale is assigned to each group site or project site within the organization, wherein the scale provides a simple means of determining the level of metrics implementation of a group. Responses from the various project sites and organization sites may then be grouped into statistical information for presentation to a user. The information can be used either statistically or in raw form by a user to make plans and changes in metric systems to enable the enterprise to become more efficient and make better use of metrics.

    Abstract translation: 提供了一种用于系统地收集企业使用的指标实施数据的方法，系统和计算机程序产品。 在一个实施例中，度量能力自我评估（MCSA）系统确定在确定企业内的组织中的度量的实现方面重要的一组信息段。 MCSA系统还确定每个信息部分的一组问题，该部分测量给定的一组信息部分内的度量的实施程度。 这些通常由企业内的一组确定并输入MCSA系统。 然后，MCSA系统向用户提供一组问题，并接收对该组问题的响应。 这些问题定期提交给组织内的每个组织和项目现场，以确保系统地收集信息。 根据答案，将一个比例分配给组织内的每个组织站点或项目站点，其中规模提供了确定组的度量执行水平的简单方法。 然后可以将各个项目站点和组织站点的响应分组为用于呈现给用户的统计信息。 信息可以由用户以统计方式或原始形式用于制定度量系统的计划和更改，以使企业变得更有效率并更好地利用指标。

    DNA encoding a novel homolog of CSBP/p38 MAP kinase
    48.
    发明授权
    DNA encoding a novel homolog of CSBP/p38 MAP kinase 失效
    编码CSBP / p38 MAP激酶新型同源物的DNA

    公开(公告)号：US06376214B1

    公开(公告)日：2002-04-23

    申请号：US08802191

    申请日：1997-02-18

    Applicant: Sanjay Kumar

    Inventor： Sanjay Kumar

    IPC: C07H2104

    CPC classification number: C07K14/705 ,  A61K38/00 ,  Y02A50/411

    Abstract: p38beta2 polypeptides and polynucleotides and methods for producing such polypeptides by recombinant techniques are disclosed. Also disclosed are methods for utilizing p38beta2 polypeptides and polynucleotides in the design of protocols for the treatment of central nervous system disorder such as senile dementia of the Alzheimer's type (SDAT), mutiple sclerosis, cerebral malaria, stroke, head trauma and spinal cord injury; cardiovascular diseases such as restenosis and atherosclerosis; inflammatory diseases such as Adult Respiratory Disease Syndrome (ARDS), Rheumatoid arthritis, Osteoarthritis, Inflammatory Bowel Disease (IBD), psoriasis, derratitis, asthma; and other such diseases or conditions associated with dysregulated or excess cytokines such as osteoporosis, sepsis due to surgical or traumatic incident, chronic renal failure, AIDs, cachexia and autoimmune conditions such as lupus erthyromatosis, host graft rejection and graft verus host disease, among others, and diagnostic assays for such conditions.

    Abstract translation: 公开了p38beta2多肽和多核苷酸以及通过重组技术产生此类多肽的方法。 还公开了在设计用于治疗中枢神经系统疾病如阿尔茨海默氏型（SDAT）的老年性痴呆，多发性硬化症，脑疟疾，中风，头部创伤和脊髓损伤的方案中使用p38beta2多肽和多核苷酸的方法。 心血管疾病如再狭窄和动脉粥样硬化; 炎性疾病如成人呼吸系统综合症（ARDS），类风湿性关节炎，骨关节炎，炎性肠病（IBD），牛皮癣，干燥性鼻炎，哮喘; 以及与失调或过量细胞因子（例如骨质疏松症，由于手术或创伤事件引起的败血症），慢性肾功能衰竭，AIDs，恶病质和自身免疫性疾病如狼疮性甲状腺病，宿主移植排斥和移植物宿主病等相关的其它这样的疾病或病症 ，以及这些病症的诊断测定。

Patent Agency Ranking